Programmed CD34+ cell therapy - Fate Therapeutics

Drug Profile

Programmed CD34+ cell therapy - Fate Therapeutics

Alternative Names: PD-L1 CD34+ cell therapy - Fate Therapeutics; ToleraCyteTM

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fate Therapeutics
  • Developer Boston Childrens Hospital; Fate Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Nov 2017 The US Patent and Trademark Office issues patent covering the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ haematopoietic cells
  • 03 Mar 2016 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 03 Mar 2016 Fate Therapeutics and Boston Children's Hospital enter into a collaboration to develop programmed CD34+ cell therapy (Fate Therapeutics, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top